Cogent Biosciences Appoints Ray Frost as SVP, Market Access
Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Express News | Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Scotiabank Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Cogent Biosciences (COGT) Initiated With a Buy at Scotiabank
Cogent Biosciences Initiated at Sector Outperform by Scotiabank
Cogent Biosciences Price Target Announced at $17.00/Share by Scotiabank
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
Piper Sandler Initiates Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $24
Cantor Fitzgerald Initiates Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $17
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $24
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $14
Cogent Biosciences Reports 2024 Financial Results and Clinical Progress
Express News | Cogent Biosciences Inc : JP Morgan Raises Target Price to $24 From $23
Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM
Baird Maintains Cogent Biosciences(COGT.US) With Hold Rating, Maintains Target Price $8
Cogent Biosciences Announces Expanded Results From OLE Portion of SUMMIT Trial
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Express News | Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $8